Physician profile
Kerry Ruia
NPI 1356486526
$11,402.81
in general payments reported to CMS, 2019-2025
39 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,711 · 2022: $2,190 · 2023: $2,451 · 2024: $1,897 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,344 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,344.14 |
| Education | $158.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,867.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,472.22 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,136.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,030.65 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $877.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $699.40 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $643.73 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $512.20 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $366.13 | 2021-2023 | Myrbetriq, Veozah |
| Axsome Therapeutics, INC. | $232.62 | 2022-2025 | Auvelity |
| Amarin Pharma, INC. | $149.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $138.55 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.94 | 2021 | |
| Merck Sharp & Dohme LLC | $128.74 | 2021-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.72 | 2022-2025 | Jardiance, Synjardy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Ruia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.